{"entity":{"id":"nct04752722","kind":"trial","name":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","aka":[],"tldr":"A phase 1/2 trial of EG-70 (phase 1) in bladder & urothelial cancer, run by enGene, Inc., now recruiting.","summary":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve is a phase 1/2 interventional study registered as NCT04752722 by enGene, Inc., with 350 participants planned, started 2021-04-22 and due to reach its primary completion in 2028-04-30. Interventions recorded: EG-70 (phase 1), EG-70 (phase 2) Master Protocol and Surfactant Bladder Pre-Rinse and EG-70 (Substudy).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04752722","url":"https://clinicaltrials.gov/study/NCT04752722"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04752722","phase":"1/2","setting":"A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment","sponsor":"enGene, Inc.","enrolled":350,"outcomes":[]},"route":"/trials/nct04752722/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}]}}